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ABSTRACT
Motivation: Cancer cell genomes acquire several genetic alterations
during somatic evolution from a normal cell type. The relative order in
which these mutations accumulate and contribute to cell fitness is
affected by epistatic interactions. Inferring their evolutionary history
is challenging because of the large number of mutations acquired by
cancer cells as well as the presence of unknown epistatic interactions.
Results:We developed Bayesian Mutation Landscape (BML), a prob-
abilistic approach for reconstructing ancestral genotypes from tumor
samples for much larger sets of genes than previously feasible. BML
infers the likely sequence of mutation accumulation for any set of
genes that is recurrently mutated in tumor samples. When applied to
tumor samples from colorectal, glioblastoma, lung and ovarian cancer
patients, BML identifies the diverse evolutionary scenarios involved in
tumor initiation and progression in greater detail, but broadly in agree-
ment with prior results.
Availability and implementation: Source code and all datasets are
freely available at bml.molgen.mpg.de
Contact: misra@molgen.mpg.de
Supplementary information: Supplementary data are available at
Bioinformatics online.
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1 INTRODUCTION
Tumor samples from cancer patients show a large variety of
genetic abnormalities that have accumulated during somatic evo-
lution from a normal cell state (Hanahan and Weinberg, 2011).
Somatic mutations are continuously acquired in individual cells,
but depending on, among other things, the fitness of the resultant
genotype, only a small fraction may reach fixation within a cell
population (Stratton et al., 2009). Fitness change induced by a
mutation can in turn depend on the genetic background, a phe-
nomenon known as epistasis (Fisher, 1918). Epistasis has been
known to play an important role in molecular evolution (Breen
et al., 2012; Kimura, 1985; Smith, 1970) and can constrain the
sequence of mutation accumulation (Gong et al., 2013;
Weinreich et al., 2005). The fitness function or landscape over
the space of all genotypes depends both on the magnitude and
sign of the epistatic interactions. Therefore, genotypes observed
in tumor samples are likely the result of a diverse set of muta-
tional paths evolving across a complex fitness landscape.
Patterns of somatic mutations observed in tumor samples
contain information, both about the evolutionary paths of
cancer progression and the epistatic gene interactions that influ-
ence them. However, extracting this evolutionary information is
challenging because the fitness landscapes are unknown, and
analyzing large datasets with hundreds of recurrently mutated
genes is computationally demanding. Owing to these difficulties,
existing computational methods for cancer progression either
constrain the set of possible evolutionary scenarios (Bozic
et al., 2010; Desper et al., 1999) or are feasible for relatively
small sets of genes (Attolini et al., 2010; Gerstung et al., 2009;
Hjelm et al., 2006).
2 APPROACH
Here, we report evolutionary progression paths (EPPs) for tumor
samples from colorectal, glioblastoma, lung and ovarian cancer
patients. The EPPs are estimated using a computational tech-
nique for reconstructing ancestral genotypes from observed
tumor genotypes, called Bayesian Mutation Landscape (BML)
(Fig. 1). The main novelty of BML is that it takes into account
unobserved ancestral genotypes and unknown epistatic gene
interactions, before inferring a probabilistic model for the accu-
mulation of somatic mutations in a population of cancer cells.
These unobserved precancer states present a systematic bias to all
methods that attempt to compute EPPs directly from tumor
samples. The nature and magnitude of epistatic interactions
also influence EPPs and can distinguish between evolutionary
scenarios with a clear sequence of genetic events from those
with multiple parallel EPPs (Fig. 1a–c). Furthermore, unlike
existing computational methods (Attolini et al., 2010; Gerstung
et al., 2009; Hjelm et al., 2006), BML incorporates several algo-
rithmic improvements that allow, for the first time, to compute
EPPs for some of the largest publicly available cancer datasets in
their entirety.
BML is based on a probabilistic model where every evolution-
ary path (with irreversible mutations) from the normal genotype
to any tumor genotype has a non-zero probability. BML first
estimates the probability P(g) that a particular combination of
mutations (denoted by genotype g) reaches fixation in a cell
population that has evolved from a normal cell genotype and
will eventually attain a tumor cell genotype (Fig. 1d). We will
refer to it as the evolutionary probability of genotype g. P(g)
equals the sum of path probabilities for every mutation path
from the normal genotype that passes through g and ends as a
tumor genotype. To get a better intuition as to what P represents,
consider the following hypothetical scenario: assume we had a*To whom correspondence should be addressed.
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database of tumor samples from large number of N cancer
patients. In addition, assume we had perfect knowledge of the
evolutionary paths followed by each tumor sample as it evolved
from a normal cell state. If n(g) was the number of samples in our
database that had g as an ancestral or current cell state, then
PðgÞ  nðgÞ=N. Because all tumor genotypes are assumed to have
evolved from an initial normal state, Pðg0Þ=1 for the non-
mutated normal genotype g0. Crucially, P(g) is not simply the
fitness of genotype g but depends on the fitness landscape over
all ancestral cell states traversed during somatic evolution, as well
as the details of evolutionary dynamics of cell populations. BML
assumes that the mutation accumulation process is irreversible
and sequential, proceeding one mutation at a time. Note that this
assumption may not be valid for large-scale karyotypic and copy
number changes that are frequently observed in tumor samples.
We therefore restrict this approach to point mutations and small
indels. We also ignore the effect of mutations already present in
the germ line.
(a) (b) (c)
(d)
(e)
(f)
Fig. 1. An overview of the BML model. Each circle represents a genotype that specifies the presence or absence of non-silent somatic mutation(s) in
either copy of each gene. Blue star represents the normal non-mutated genotype, blue circles represent genotypes that may contain somatic mutations,
but have not yet attained the phenotype of uncontrolled growth, and red circles represent cancer genotypes. Note that there may be additional
unobserved tumor genotypes (empty red circles). a, b and c show the fitness profile and the distribution of observed samples (red circles) for three
evolutionary scenarios. In a, mutations in genes A and B independently give rise to a genotype that is a fitter relative to the normal genotype. In contrast,
b shows a scenario where there is positive fitness epistasis between genes A and B. However, there is no clear sequence of mutational events in A and B. c
depicts a scenario where there is positive fitness epistasis between A and B, but the path through B encounters a fitness valley. This scenario is known as
sign epistasis because the sign of fitness difference between B mutated and non-mutated states depends on the mutation state of A. In this case, an
unambiguous sequence of mutations in A and B can be inferred (Supplementary Note S1). d, Evolutionary probability P(g) for any ancestral genotype g
contains information from all paths composed of sequential, irreversible mutations, from normal genotype to any tumor genotype that pass through g.
Each possible path has a non-zero probability, and P(g) equals the sum of all such path probabilities. e, Schematic for the algorithm. We use both
observed tumor samples (filled red circles) and imputed evolutionary paths to infer the probabilities P(g) of genotype g. P(g) is represented by a Bayesian
network, that is optimized for the best choice of imputed paths. Once a Bayesian network is selected, a recursive algorithm is used to infer the likely EPP.
f, Efficiency of the pruning scheme and the BML algorithm for glioblastoma, lung and ovarian cancer datasets. Cutoff shows the minimum number of
samples in which each retained gene was mutated to be considered recurrent (Section 3). Note that the search space is exponential in the number of
unpruned edges in the worst case. Run time results are4100 random restarts of the algorithm on 2.4GHz Intel Core i5 processor and 4 GB memory
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BML estimates the evolutionary probabilities using a graph-
ical model known as a Bayesian network. Bayesian networks
describe a large class of probability distributions that can be
represented as directed acyclic graphs (DAGs). They have previ-
ously been applied to gene expression analysis (Friedman, 2000),
as well as copy number variations in cancer (Bulashevska et al.,
2004). Figure 1e provides a schematic for the algorithm. Inferring
the distribution P over all genotypes is complicated because of a
systematic bias, as the highest probability precancer genotypes
(Fig. 1e, blue circles) are not present in the input, which consists
of samples from diagnosed cancer patients (red circles). BML
estimates P for these ancestral genotypes by imputing likely evo-
lutionary paths (in the form of a bifurcating tree). The collection
of paths connecting a set of vertices (observed tumor genotypes)
to a common vertex (the normal genotype) can always be repre-
sented by a tree. The internal nodes of the tree represent ancestral
genotypes and are treated as unobserved samples. These ances-
tral genotypes, along with the observed samples are then used to
estimate a Bayesian network. Because we do not know the true
paths followed by observed samples, we perform an additional
optimization step, where we perturb the paths using a class of
tree rearrangements known as nearest neighbor interchange
(NNI) (Felsenstein, 2004) and repeat the process until the algo-
rithm encounters a local optimum in tree space. The Bayesian
network estimates P up to an overall normalizing factor, that is
later set by requiring that the evolutionary probability for the
non-mutated normal genotype is one. The inferred Bayesian net-
work representation of P(g) is then used to reconstruct the most
likely EPP using a recursive algorithm (see Section 3).
Another advantage of using Bayesian networks is their ability
of separating direct from indirect epistatic interactions, with net-
work edges denoting direct epistatic interactions. Because nega-
tive epistatic interactions are difficult to separate from the
scenario in Figure 1a (Supplementary Note S1), we restricted
BML to model co-occurrence of mutations that provide a reli-
able signature of positive epistasis (Fig. 1b and c and
Supplementary Note S1). Together with the algorithmic im-
provements introduced to BML modeling, based on pruning
large regions of the search space (see Section 3 and
Supplementary Note S2), this approximation of P allows for
extremely efficient computations (Fig. 1f). As a result, BML
can be used to perform comprehensive bootstrap analysis for
tumor datasets with many more recurrently mutated genes
than previously feasible.
3 METHODS
In this section, we discuss algorithms for learning the structure and par-
ameters of the Bayesian network and for reconstructing the EPPs from
observed tumor samples.
3.1 Datasets
We performed BML analysis for colorectal (Bamford et al., 2004;
Sj€oblom et al., 2006), glioblastoma (Parsons et al., 2008; TCGA consor-
tium, 2008), lung (Ding et al., 2008) and ovarian cancer samples (TCGA
consortium, 2011). The colorectal cancer dataset was obtained from the
supplement to the paper by Attolini et al. (2010). Glioblastoma, lung and
ovarian cancer datasets were all downloaded from publicly available
databases maintained by The Cancer Genome Atlas (TCGA) and the
International Cancer Genome Consortium (ICGC) (Supplementary
Table S1). Each dataset was preprocessed to retain non-silent mutations,
identify recurrently mutated genes and coarse grain the data such that
each gene can take two states, mutated and non-mutated. For glioblast-
oma, we combined the data from two sequencing studies (Parsons et al.,
2008; TCGA consortium, 2008). We also removed one tumor sample in
glioblastoma that was identified as hyper mutated in the original sequen-
cing study (Parsons et al., 2008). We filtered genes that were mutated too
infrequently by imposing a cutoff on the number of samples with muta-
tions in a gene. For each dataset, this cutoff was chosen as the smallest
number (greater than three) such that the number of retained genes was
less than the number of available samples. The final input to our method
is a matrix of genes versus tumor samples with 0/1 entries indicating the
absence/presence of a non-silent somatic mutation in a gene for each
tumor sample (Fig. 1f). We should point out that the set of genes used
as an input to our method could also be restricted according to appro-
priate criterion (e.g. mRNA expression). This can be achieved via algo-
rithms for restricting input gene sets such as the MutSigCV algorithm
(Lawrence et al., 2013) or the somatic functional events in Ciriello et al.
(2013). In the absence of such functional information, the events in the
inferred paths must not be assigned functional importance and must be
interpreted as the set of events that frequently occur during the process of
cancer progression.
3.2 The BML model
BML models the evolutionary probabilities over the genotype space as
a probability distribution that is represented by a Bayesian network, up
to an overall normalizing factor. The normalizing factor is then ob-
tained by imposing the constraint that Pðg0Þ=1 for the normal genotype
g0 and appropriately scaling the Bayesian network probabilities. The net-
work is defined on a set C of binary random variables that represent
mutations of the genes, whereas edges represent direct epistatic inter-
actions. Formally, a Bayesian network BðG;Þ is specified by G,
a DAG whose vertices are the genes in C, and a set of param-
eters =fCjC 2 Cg, representing conditional probabilities CðcjÞ  Pr
ðC=cjC=Þ for each gene C given the state of its parents C in G
(Koller and Friedman, 2009). Let D denote a m n data matrix with
binary entries. The columns of D represent the set of genes
C=fC1; . . .Cmg, and rows represent the set of samples S=fS1; . . .Sng,
such that Dij=1 if gene Ci is mutated in sample Sj (with respect to a
reference state designated as normal) and 0 otherwise. The data matrix
can be used to compute sufficient statistics for learning the network struc-
ture, in the form of counts nc; for the number of samples where gene
C= c when its parents =. We use the Bayesian information criterion
(BIC) for selecting candidate structures:
log PrðDjBÞ 
X
C2C
FamðC;CÞ ð1Þ
where FamðC;CÞ is the BIC score for a family fC;Cg consisting of
each gene and its parents and is given by
FamðC;CÞ=max C
X

X
c
nc; log½CðcjÞ  log n
2
( )
ð2Þ
The BIC score is known to be statistically consistent in the sense that
given sufficiently many samples from an underlying Bayesian network,
we can learn the true structure by maximizing the BIC score.
3.2.1 Learning the evolutionary probability distribution To cor-
rectly learn the evolutionary probability P, we need to consider a dataset
containing both the given cancer genotypes and the unobserved precancer
ones. If the samples are lacking data from certain regions of the state
space, the inferred network parameters will be biased accordingly. To
account for this problem, we construct bifurcating trees, with normal
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genotype at the root (a node of degree one), tumor samples at the leaves
and all other internal nodes as degree three. If O is the input dataset of
observed tumor samples and T denotes the degree three internal nodes
and the root of the bifurcating tree, then the complete data D=O [ T,
and this is used for estimating the Bayesian network in Equation (1).
We also make the following simplifications in selecting the trees and
model parameters for reasons of computational efficiency. First, we
assume that the accumulation of mutations in a sample is irreversible,
with 0–1 transitions from the root to the leaf. The root node in our
problem is the normal state with all genes in state 0. We choose the
state of any gene at any internal vertex as 1 only if all its descendant
leaves are in state 1.
The second restriction we make is motivated by our model choice.
Because the probabilities that we infer represent the chance of a combin-
ation of mutations reaching fixation in a cell population, as it evolves
from a normal state, the probabilities for the mutated states must be
smaller than those of the normal state. We use a simple and computa-
tionally efficient heuristic criterion to incorporate this feature of BML by
requiring that the number of samples in D with a mutation in any gene
should not be more than half the total number of samples. Note that this
condition can always be satisfied by choosing an appropriate labeling of
the internal nodes. This holds because n, the total number of nodes,
equals the sum of s observed samples, one normal and s+1 2 degree
three internal nodes, which yields n=2s.
Third, we restrict the parameters of our model such that given any
genotype, the probability of accumulating a mutation in a gene does not
decrease on acquiring a mutation in another gene (see Supplementary
Methods for details). Formally, we require the conditional probabilities
for a gene C 2 C to be mutated, given the state of its parents C  C, to
obey the following constraints.
PrðC=1jC=AÞ  PrðC=1jC=BÞ8B  A ð3Þ
where B  A means that all genes in C that are mutated in state B
are also mutated in A. Prior attempts at modeling the dynamics of
cancer progression have included similar parameter constraints
(Gerstung et al., 2009; Hjelm et al., 2006). One justification for this con-
straint is that co-occurrence of mutations in any pair of genes is unlikely
by chance and serves as a reliable test for positive epistasis, whereas
mutations that show a tendency to be mutually exclusive are not neces-
sarily because of epistatic interactions (Supplementary Note S1) and rep-
resent a weaker signal to be resolved at the small sample sizes of available
datasets. Note that this constraint does not imply a monotonically
increasing fitness landscape.
The structure learning problem with these simplifications is to estimate
the tree T	 and Bayes net B	 that maximize log PrðDjBÞ. WithD=T [O,
we can formally write our objective as
ðT	;B	Þ=arg max
T;B
log PrðDjBÞ ð4Þ
3.2.2 Bayesian network structure and parameter learning
algorithm In this section, we describe a heuristic for efficiently learn-
ing the distribution P. Given the leaves and internal nodes of the tree, we
search for the optimal DAG using the method of ordering-based search
(OBS) (Teyssier and Koller, 2005). OBS initializes an ordering on the
variables and constrains each variable to choose parents exclusively
from the set of its predecessors in the ordering. The algorithm then
searches the space of all orderings by flipping the order of any pair
of variables adjacent in the ordering. Note that this ordering is not
the same as the ordering of mutations in genes during somatic evolution.
The search over tree space was performed by a class of local moves
known as NNI (Felsenstein, 2004). We use two asymptotic pruning re-
sults that allow us to greatly restrict the search space (Supplementary
Note S2).
Algorithm 1: BML Structure learning.
1. Perform a global pairwise pruning for each pair of genes (Supplemen-
tary Note S2).
2. Randomly initialize a bifurcating tree with observed samples as leaves
and normal state as root and assign internal node labels.
3. Perform pairwise local pruning (Supplementary Note S2).
4. Find the DAG that maximizes BIC score and obeys Equation (3) using
OBS.
5. Perturb the tree using NNI and repeat the search steps 3 and 4 until
local optimum.
After performing structure learning using BIC, we used an empirical
Dirichlet prior for learning the parameters of the Bayes Net. For each
gene C, the parameters were chosen as ðC=cjC=Þ=ðnc+cÞ=
ðn0+n1+1Þ, where the hyper parameter c denotes the fraction of
samples in D that have C= c, and nc is the number of samples where
C= c and C=.
3.3 Reconstructing the most likely EPP
The analysis performed in Supplementary Note S1 suggests that the most
probable ancestor for a given genotype is the one with highest evolution-
ary probability. We use this observation to reconstruct the most likely
EPPs, presented in Figure 2, using a recursive algorithm. Briefly, the
algorithm starts with a set of most likely states with three mutations
and retraces their mutational history by connecting each genotype to
their most likely ancestral state (i.e. the ancestral state with largest P).
The algorithm takes as input the inferred P and parameters k41 and
c51. Paths are initialized starting from all genotypes representing com-
binations of kmutations, which are present in the observed data and have
a probability larger than a cutoff c 	mk, where mk equals the largest
probability of a genotype with k mutations. The user can vary the level
of detail in the reconstructed paths by varying c, and the size of the paths
with k. At each subsequent step i5k of the algorithm, for each genotype,
the algorithm identifies the most likely ancestral state with i– 1 mutations,
by choosing the one with the highest P. The algorithm then adds a set of
nodes with i – 1 mutations that are either identical to the genotype of at
least one observed sample and have a probability larger than c 	mk, or
were identified as the likely ancestral state for a node retained at the
previous step i+1. This process is repeated all the way up to the node
representing the normal genotype. Figure 2 shows the likely paths with
c=0.3 and k=3.
4 RESULTS
BML analysis for each dataset was accompanied with 1000 para-
metric bootstrap replicates to assess the robustness of the
inferred Bayesian network. Figure 2 shows the highest probabil-
ity genotypes and the most likely paths of progression for each
dataset. Note that the trees shown in Figure 2 are not the same as
the full bifurcating tree used by the algorithm, but only the high
probability genotypes traversed by tumor samples (Fig. 1e, see
Section 3).
4.1 Most likely paths of progression
The temporal order of mutations has perhaps been best studied
in colorectal cancer (Fearon and Vogelstein, 1990). The temporal
order of APC, KRAS and TP53 mutations was also investigated
computationally in Attolini et al. (2010). Therefore, we first pre-
sent the results of BML analysis for the colorectal cancer dataset
analyzed by Attolini et al. (2010) for comparison. Their results
support the hypothesis that APC mutations are more likely to
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initiate tumorigenesis than KRAS mutations, which in turn are
more likely than TP53 mutations. BML estimates for the evolu-
tionary probabilities of initial mutations (Fig. 2a) agree with
these conclusions of Attolini et al. (2010). However, BML detects
a robust positive epistatic interaction (bootstrap confidence
498%) between APC and TP53. As a consequence, conditional
on APC being the initial mutation, a TP53 mutation is more
likely than a KRAS mutation. Therefore, in tumor samples
Fig. 2. Most likely paths followed by (a) colorectal, (b) glioblastoma, (c) lung adenocarcinoma and (d) ovarian cancer tumor samples. In general, there
are several other low-probability events that may occur, but have been left out for clarity. Color for a genotype g with kmutations is scaled according to
its relative probability PðgÞ=mk (decreasing from darker shade to light), where mk is the maximum probability for a node with k mutations (Section 3).
The bar plots (blue) show the number of samples with mutations in a given gene for the initial events shown in the paths
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that contain mutations in each of the three genes, the most likely
sequence is an APC mutation followed by a TP53 mutation,
which is then followed by KRAS.
We next performed BML analysis for a set of 22 recurrently
mutated genes in 194 glioblastoma samples. A model proposed
by Ohgaki et al. (2004) and Ohgaki (2007) indicated that a TP53
mutation is the initiating event in secondary glioblastomas, fol-
lowed most commonly by EGFR and PTEN mutations. In the
case of primary glioblastomas, TP53, EGFR and PTEN muta-
tions are present in roughly equal frequencies and provide alter-
native paths of tumor initiation. BML recapitulates these
findings and also identifies alternative lower probability paths
that are initiated by NF1, PIK3R1 and PIK3CA mutations
(Fig. 2b). The BML prediction that an initiating mutation in
NF1 is less likely than TP53 also agrees with the computational
analysis of Attolini et al. (2010). For lung cancer, BML analysis
of 51 recurrently mutated genes in 161 adenocarcinoma samples
inferred KRAS, TP53, EGFR and STK11 mutations as likely
early events in alternative paths during cancer progression
(Fig. 2c). TP53 and KRAS mutations tend to co-occur during
the later steps of mutation accumulation. In contrast, EGFR and
KRAS mutations are mutually exclusive and, as reported by
(Ding et al., 2008), correlated with the smoking status of the
patient, with EGFR mutations more common in non-smokers.
Applied to 192 recurrently mutated genes in 326 ovarian
cancer samples, BML inferred TP53 as the most likely initiator
of tumor cells. TTN is the second most common mutation fol-
lowed by several other recurrently mutated genes. BML predicts
that TTN mutation is unlikely before TP53, but the TP53-TTN
genotype is the most likely among states with two mutations in
the observed tumor samples (Fig. 2d).
4.2 Fitness epistasis and sequence of genetic events
Fitness epistasis refers to a departure from additivity in the effect
of mutation combinations with respect to their contribution to
log fitness (Fisher, 1918). Epistatic interactions contribute both
to the distribution of observed tumor samples in the genotype
space as well as the evolutionary probability (Fig. 1). Even
though BML is not constrained to any specific model of evolu-
tionary dynamics, it is instructive to estimate and interpret the
evolutionary probabilities for a population genetics model used
in prior studies (Attolini et al., 2010; Komarova et al., 2003;
Michor et al., 2004). The model is a stochastic process that de-
scribes the evolutionary dynamics of a population of cells as they
randomly accumulate mutations (with gene-dependent mutation
rates) during cell division, and compete for resources based on
the fitness of the genotype (Supplementary Note S1). This model
can be used to establish the following connection between epi-
static interactions and the evolutionary probability for the scen-
arios depicted in Figure 1a–c (Supplementary Note S1):
(i) Positive fitness epistasis (in Fig. 1b and c) leads to a
tendency for mutations in A and B to co-occur and
implies that the double-mutant genotype satisfies
PðABÞ  PðAÞPðBÞ.
(ii) Sign epistasis (Fig. 1c) implies PðAÞ44PðBÞ, and an un-
ambiguous ordering of mutations leading to the double
mutant genotype can be inferred. Furthermore, if
mutations in A occur at a sufficiently high frequency
and/or the epistatic interaction is particularly strong,
then, PðAÞ  PðABÞ  PðBÞ.
These observations suggest that epistatic interactions can lead
to scenarios where we can unambiguously infer the sequence of
genetic events (Fig. 1c and Supplementary Note S1). We use
BML estimates for P to detect such evolutionary scenarios by
identifying pairs of genes where the double-mutant genotype has
an evolutionary probability in between the two single-mutant
genotypes. Figure 3a shows one such instance for each dataset
analyzed.
The case of TTN, the gene that codes for the largest human
protein and is frequently mutated across multiple cancer types
(Balakrishnan et al., 2007; Greenman et al., 2007), highlights the
utility of this criterion. In particular, tumor samples from ovar-
ian cancer patients show a tendency of TP53 and TTNmutations
to co-occur, suggesting a possible epistatic interaction. However,
BML analysis predicts that TTN mutations rarely precede TP53
mutations (Fig. 3a) and are unlikely to initiate tumor formation.
This conclusion is in agreement with the original TCGA publi-
cations that did not identify TTN mutations as significant in
initiating tumor formation (TCGA consortium, 2011).
Although frequent mutations in TTN may likely be due to its
huge length and not entirely due to functional reasons, there
have been prior experimental studies that have suggested a pos-
sible role for TTN during cell division (Machado et al., 1998;
Machado and Andrew, 2000; Qi et al., 2008). A definite answer
regarding the role of TTN mutations and their contribution to
tumor cell fitness would require further experimental
investigation.
4.3 Simulations validate the improvement in accuracy and
robustness with BML
We performed a simulation-based parametric bootstrap
(Friedman et al., 1999) for validating our method as well as
demonstrating the effect of unobserved genotypes on the recon-
struction algorithm. Parametric bootstrap involves learning a
model from the given data and simulating the learnt model to
generate new datasets for learning. This way we have access to
ground truth for the simulated datasets and can estimate both
the accuracy and robustness of the learning algorithm. We per-
formed parametric bootstrap by simulating samples from the
DAG learnt by BML on each of the datasets. We only retained
those simulated samples that had at least one mutation and
where all the mutations were present in at least one observed
tumor sample. Because we wanted to assess the uncertainty in
estimated evolutionary probabilities, our goal was to simulate a
dataset where the region with unobserved precancer states closely
mimics real data. This is important because the retained geno-
types specify how many and which combination of mutations are
needed before a cell population becomes capable of uncontrolled
growth. The number of retained simulated samples was set equal
to the number of observed tumor samples in each case.
Figure 3b–d shows the results from bootstrapping of 1000
simulated datasets for our approach with and without the tree
estimation and parameter constraints. The former scenario re-
flects the DAG inferred by the full BML model, which takes into
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account and aims to correct for the bias due to unobserved
precancer genotypes. This is compared with standard Bayesian
network learning where the unobserved states (represented by the
internal nodes of the tree) are not included. Figure 3b shows the
probability of mutations for 10 frequently mutated genes for
the simulated Bayesian network in each case. These genes were
selected based on an ordering that the algorithm automatically
assigns to the genes (Section 3). The mutation probabilities for
the BML model are consistently lower, as expected, because the
standard algorithm does not take into account the probability
mass from ancestral states that have fewer mutations than in the
observed samples. As can be seen in Figure 3c and d, including
the tree and parameter constraints leads to both fewer false posi-
tives and fewer false negatives in inferred edges, at a fixed con-
fidence level.
By default, we constrain the parameters of our model to ac-
count for patterns of mutation co-occurrence (Section 3). To test
the assumption in a model-based manner, we also implemented
an alternative version of our method without any parameter
constraints for glioblastoma and lung cancer. For glioblastoma,
our method did not infer any additional edges. For lung cancer,
this method inferred an edge between EGFR and KRAS, but
with a low bootstrap confidence of 45%.
5 DISCUSSION
Modeling the evolutionary events leading to cancer and charac-
terizing the fitness landscape of cancer cells promises innovative
applications in clinical cancer research (Merlo et al., 2004). BML
allows the reconstruction of likely ancestral genotypes and the
paths of mutation accumulation in greater detail than existing
methods. BML accomplishes these tasks owing to several algo-
rithmic improvements that take into account the unobserved
precancer genotypes that provide a systematic bias to EPP re-
construction, as well as the effects of unknown epistatic
interactions.
We should emphasize that the goal of BML is not to classify
somatic mutations as drivers or passengers; rather BML recap-
itulates the likely sequence of somatic mutation accumulation in
recurrently mutated genes. It should also be noted that the bifur-
cating tree used by BML is simply an efficient data structure to
represent paths and does not necessarily imply a hierarchical
ordering of mutations. This distinction is important because
somatic evolution occurred independently in each cancer patient
and different tumor samples do not have a shared evolutionary
history. Even though the genotypes at the internal nodes of the
bifurcating tree allow us to correct for the systematic bias due to
unobserved precancer genotypes, the estimated evolutionary
probabilities are still only an approximation of the true distribu-
tion. However, since the estimated P are computed after taking
into account the inferred precancer genotypes, they also incorp-
orate the evolutionary aspect of the true evolutionary
probabilities.
There are some obvious limitations of BML analysis because it
does not include copy number and genomic rearrangements that
likely provide alternative paths for tumor initiation and progres-
sion. Another source of complexity is the existence of genetic
heterogeneity within individual tumor samples (Nik-Zainal
Fig. 3. (a) Sequence of genetic events. Box plots for 1000 bootstrap replicates showing examples of strong departures from additivity in log(P) for each
dataset. The third row (red) shows the computed log(P) and the fourth row (gray) shows the sum of the two single mutated states. Mutations in these
genes show a tendency to co-occur, suggesting that the departures from additivity are due to positive epistasis. Furthermore, a clear sequence of genetic
events can be inferred (along the red box plots), suggesting the presence of a fitness valley along one (blue single mutant) of two possible paths to reach
the double mutant genotype. The case of TP53-TTN genotype in ovarian cancer shows how TTN mutations, despite their recurrence, rarely initiate
tumor progression. (b–d). Simulation-based parametric bootstrap for each of the datasets. Blue (box plots in b and curves in c and d) show the results for
the BML model that uses inferred ancestral information, whereas the results for standard Bayesian network learning algorithm are in red. The box plots
in b show P(g) for single mutated states for 10 frequently mutated genes. These genes were selected based on an ordering that the algorithm automatically
assigns to the genes (Section 3). Vertical axes in c and d represent the percentages of bootstrap confidence, whereas the horizontal axes represent the
number of edges in the inferred networks that were false and true positives, respectively
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et al., 2012), as well as the role of tumor microenvironment
during cancer progression (Bissell and Hines, 2011). BML ig-
nores the possible cooperative interactions between subclonal
cell populations within a tumor and between tumor and sur-
rounding stromal cells. These are all important avenues that
are left for further exploration.
Aside from these limitations, an extensive bootstrap analysis
demonstrates that BML estimates of P are accurate and robust
(Fig. 3). Simulations (Fig. 3c and d) also show that BML iden-
tifies epistatic interactions with greater accuracy than a naive
network reconstruction algorithm. At the same time, BML is
scalable for application to some of the largest available cancer
datasets (Fig. 1f). Therefore, BML is an efficient and powerful
tool that brings us a step closer to understanding the evolution of
the cancer genome.
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